Female-founded Finnish startup Audicin raises €1.6 million to develop audio treatments for nervous system overstimulation

April 1, 2026 at 08:35 AM UTC
EU-Startups
Original: EN
Female-founded Finnish startup Audicin raises €1.6 million to develop audio treatments for nervous system overstimulation

Finnish NeuroTech startup Audicin has secured €1.6 million in new funding to advance its innovative audio treatments for nervous system overstimulation. This investment, bolstered by existing investors and Business Finland, will enable the company to scale its technology and integrate it into a wider range of applications, addressing the growing need for real-time stress recovery and focus enhancement. The funding round brings Audicin's total capital to approximately €2.5 million, underscoring significant confidence in its unique approach to digital wellness. Audicin's technology utilizes brainwave entrainment and music neuroscience to create composed audio tracks with embedded binaural beats. These scientifically designed soundscapes are intended to guide the brain into states of calm, recovery, or focus, operating discreetly in the background of daily activities. The company is also developing a standalone, offline Sleep Headband and offers an SDK, "Audicin for Apps," allowing third-party platforms to embed its neuro-audio protocols directly into their own products. The fresh capital will be instrumental in commercializing Audicin's app, its new Sleep Headband, and the "Audicin for Apps" SDK. With a substantial sales pipeline spanning defence, athletic performance, and wellness sectors, Audicin is poised for significant growth. This expansion is particularly relevant within the European digital policy landscape, emphasizing the development of independent digital solutions and robust health-tech innovations.

Curated and translated by Europe Digital for our multilingual European audience.

Source Information

Publication: EU-Startups
Published: April 1, 2026 at 08:35 AM UTC
All rights remain with the original publisher.